During this segment, Scott Gottlieb, MD; Brian Kiss, MD; Michael Kolodziej, MD; and Ted Okon, MBA, continue the discussion regarding issues that affect new oncology care models, including drug wastage, patient compliance, and treatment costs.
As more oncology drugs are being dispensed via practice-based pharmacies, intervention is needed to reduce waste, Dr Kolodziej comments. Also, compliance remains an issue even with the advent of practice-based pharmacies.
Although some states have passed parity laws, meaning that patient out-of-pocket (OOP) costs for oral medications should not be greater than OOP costs for intravenous medications, high OOP costs remain a barrier to patient access to treatment.
Dr Kiss discusses the buy-and-bill model’s impact on oncology and suggests that payment reform is necessary. Oncologists should be compensated for providing cognitive and technical services, he believes, rather than for dispensing chemotherapy drugs.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Study: Anxiety May Increase Acute Exacerbation Risk for Older Patients With COPD
May 2nd 2024Older patients with chronic obstructive pulmonary disease (COPD) and anxiety exhibited exacerbated symptoms, increased comorbidities, and frequent acute exacerbations of COPD (AECOPD), emphasizing the need for routine psychiatric screening in COPD management.
Read More
Specialty Pharmacists at the Forefront: Elevating Care for Rare Diseases
May 1st 2024In the US, a disease is considered rare when it affects fewer than 200,000 persons, or 1 in every 1500 individuals, with an estimated total of 25 to 30 million Americans overall living with a rare disease at any given time.
Read More